Fat-Derived stem cells injected into spine to fight progressive MS

NCT ID NCT06592703

Recruiting now Disease control Sponsor: Rennes University Hospital Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This early-phase trial is testing whether repeated injections of stem cells from donated fat tissue are safe for people with primary progressive multiple sclerosis (MS). Ten participants will receive the cells directly into the spinal canal. The main goal is to check for serious side effects, but researchers will also watch for any signs that the treatment might slow disability progression.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: donor fat-derived stem cells (mesenchymal stromal cells)
What this could lead to: If safe and effective, this could point toward a new way to slow or stop worsening disability in primary progressive multiple sclerosis.
What could go wrong: This is a very early, small phase 1 trial focused on safety, not proof of benefit. The treatment may not work, and there are risks from the injections and the cells themselves.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

multiple sclerosis primary progressive multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE SCLEROSIS

Contacts and locations

Locations

APHP Henri Mondor
ACTIVE_NOT_RECRUITING

Créteil, France
CHU Rennes
RECRUITING

Rennes, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.